NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab (MEDI4736) and Tremelimumab in Muscle-invasive Urothelial Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 14 May 2019
Price : $35 *
At a glance
- Drugs Cisplatin (Primary) ; Doxorubicin (Primary) ; Durvalumab (Primary) ; Methotrexate (Primary) ; Tremelimumab (Primary) ; Vinblastine (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NEMIO
- 09 May 2019 Planned End Date changed from 1 Feb 2022 to 1 Nov 2024.
- 09 May 2019 Planned primary completion date changed from 1 Feb 2022 to 1 Nov 2023.
- 17 Dec 2018 Status changed from not yet recruiting to recruiting.